---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-21-000103"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:38:26.886912+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gossamer Q3 net loss $60.2M ($0.80/shr); PAH study topline delayed to H2 2022

## Summary
- Net loss $60.2M for Q3 2021 vs $57.8M prior year, R&D $43.2M, G&A $12.5M.
- Cash, equivalents and securities $366M as of Sept 30, 2021; sufficient into H2 2023.
- Phase 2 TORREY (PAH) topline results now expected H2 2022 due to COVID-19 delays.
- Phase 2 SHIFT-UC (ulcerative colitis) completed enrollment; topline Q2, treat-through data Q4 2022.
- GB5121 advanced to Phase 1 healthy volunteers; GB7208 (MS) Phase 1 expected H2 2022.

## SEC filing metadata
- accession: 0001728117-21-000103
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811721000103/0001728117-21-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811721000103/goss-20211108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-21-000103
- JSON: https://secwatch.observer/filing/0001728117-21-000103.json
- Plain text: https://secwatch.observer/filing/0001728117-21-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.